Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I will continue to think that last year's offering was a mistake.

Water under the bridge.

MNTA’s liquidity is substantially improved from just a few months ago, so I think it’s reasonable to assume that there will be no financings in the near future. Hence, MNTA has no economic incentive to give up something of consequence in order to boost the share price in the short run.

Posters who trade MNTA and think that MNTA’s economic incentives are aligned with theirs—and who thereby think some kind of comprehensive settlement with Teva is in the cards—strike me as unseasoned.